Aarti Pharmalabs Share Price

NSE
AARTIPHARM •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Aarti Pharmalabs
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
69.07% Gain from 52W Low
24.3
Dividend yield 1yr %
Below industry Median
0.5

Aarti Pharmalabs Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Aarti Pharmalabs Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
537.78 Cr
458.03 Cr
555.49 Cr
505.77 Cr
448.69 Cr

Aarti Pharmalabs Yearly Revenue

Mar 2024Mar 2023Mar 2022
1857.5 Cr
1947.55 Cr
1202.46 Cr

Aarti Pharmalabs Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
73.99 Cr
54.62 Cr
55.45 Cr
65.25 Cr
52.76 Cr

Aarti Pharmalabs Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022
216.9 Cr
193.49 Cr
122.25 Cr
Aarti Pharmalabs Result Highlights
  • Aarti Pharmalabs Ltd reported a 17.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 20.6%.

  • Its expenses for the quarter were up by 13.2% QoQ and 17.5% YoY.

  • The net profit increased 35.5% QoQ and increased 40.2% YoY.

  • The earnings per share (EPS) of Aarti Pharmalabs Ltd stood at 8.2 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Aarti Pharmalabs shareholding Pattern

Promoter
44.7%
Foreign Institutions
8.6%
Mutual Funds
3.9%
Domestic Institutions
10.4%
Public
36.3%
Promoter
46.1%
Foreign Institutions
7.4%
Mutual Funds
4.9%
Domestic Institutions
11.3%
Public
35.2%
Promoter
46.5%
Foreign Institutions
7.1%
Mutual Funds
4.7%
Domestic Institutions
11.5%
Public
35%
Promoter
46.5%
Foreign Institutions
8.3%
Mutual Funds
2.7%
Domestic Institutions
10%
Public
35.2%
Promoter
46.5%
Foreign Institutions
8.2%
Mutual Funds
2%
Domestic Institutions
9.9%
Public
35.4%
Promoter
46.3%
Foreign Institutions
8.4%
Mutual Funds
2.7%
Domestic Institutions
10.6%
Public
34.7%

Aarti Pharmalabs Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
7
Bearish Moving Averages
9
5Day EMA
742.70
10Day EMA
746.90
12Day EMA
747.10
20Day EMA
743.50
26Day EMA
738.30
50Day EMA
715.90
100Day EMA
684.80
200Day EMA
641.90
5Day SMA
751.40
10Day SMA
748.90
20Day SMA
746.80
30Day SMA
751.40
50Day SMA
704.20
100Day SMA
671.60
150Day SMA
661.40
200Day SMA
648.60
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
263290 Rs
715182 Rs
Week Rs
372420 Rs
1044010 Rs
Month Rs
232006 Rs
628691 Rs
Resistance & Support
727.33
Pivot
Resistance
First Resistance
744.67
Second Resistance
765.33
Third Resistance
782.67
Support
First Support
706.67
Second support
689.33
Third Support
668.67
Relative Strength Index
46.64
Money Flow Index
52.51
MACD
8.74
MACD Signal
13.79
Average True Range
39.91
Average Directional Index
16.24
Rate of Change (21)
-7.98
Rate of Change (125)
13.69

Aarti Pharmalabs Company background

Founded in: 2019
Managing director: Narendra Jagannath Salvi
Aarti Pharmachem Limited was incorporated as a Public Limited Company in 2019. The Company is engaged in manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine Derivatives situated in India.In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005 commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016. It expanded block for CSD, Vapi and API, Tarapur units in 2022.The Scheme of Arrangement for the demerger of Pharma Business Undertaking from Aarti Industries Limited into its wholly owned subsidiary Aarti Pharmalabs Limited was effective on October 17, 2022 and operational from July 1, 2021. Pursuant to the said Demerger Scheme, Aarti Industries Limited hived off its Pharmaceutical Division into a separate entity Aarti Pharmalabs Limited and accordingly, all the assets and liabilities pertaining to the Pharma Business Undertaking got transferred and vested into the Company effective from the above said Date.Thereafter, the Company in 2023 commercialised Block V at Tarapur Unit 4. Again, it enhanced Xanthine capacity to 5,000 TPA in 2023.9,06,26,008 Equity Shares of Rs 5/ each got listed effective January 30, 2023.
Read More

Aarti Pharmalabs FAQs

Aarti Pharmalabs share price is ₹727 in NSE and ₹726.95 in BSE as on 25/3/2025.

Aarti Pharmalabs share price in the past 1-year return was 63.33. The Aarti Pharmalabs share hit a 1-year low of Rs. 430 and a 1-year high of Rs. 837.25.

The market cap of Aarti Pharmalabs is Rs. 6561.32 Cr. as of 25/3/2025.

The PE ratios of Aarti Pharmalabs is 28.36 as of 25/3/2025.

The PB ratios of Aarti Pharmalabs is 3.84 as of 25/3/2025

The Mutual Fund Shareholding in Aarti Pharmalabs was 3.93% at the end of 25/3/2025.

You can easily buy Aarti Pharmalabs shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Aarti Pharmalabs stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -